Long-acting, injectable risperidone, the first second-generation antipsychotic available in the United States in this formulation, is no better than oral antipsychotics for the treatment of unstable schizophrenia, a new study published in the March 3 issue of the New England Journal of Medicine suggests.
In a randomized study of more than 300 Veterans Affairs (VA) patients, investigators found injectable risperidone did not significantly decrease hospitalization rates or improve symptoms, social function, or quality of life compared with those treated with "clinicians' choice" of oral antipsychotics. The risperidone-treated group also reported more adverse effects.
No Benefit, More Side Effects With Injectable Risperidone
Комментариев нет:
Отправить комментарий